Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
Véronique Minard‐Colin(Inserm), Birgit Burkhardt(University Hospital Münster), Franco Locatelli(Bambino Gesù Children's Hospital), Lida Bubuteishvili‐Pacaud, Jochen Buechner(Oslo University Hospital), Shannon L. Maude(Children's Hospital of Philadelphia), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Joerg Krueger(Hospital for Sick Children), Theodore W. Laetsch(Children's Hospital of Philadelphia), Andishe Attarbaschi(Cancer Research Institute of the Slovak Academy of Sciences), Rakesh Awasthi(Novartis (Switzerland)), Simon Newsome(Novartis (United Kingdom)), Berta González Martínez(Hospital Universitario La Paz), Jaclyn Davis(Bristol-Myers Squibb (United States))
Cited by 6
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738